HeraMED [ASX:HMD] has developed an innovative, connected pregnancy monitoring solution called HeraBEAT that is designed to provide accurate, scientifically optimised data about a mother and unborn child.

It has joined forces with the prestigious Mayo Clinic and an AI driven system that will digitally, in real time, link an expectant mother to a raft of support and spot warning signs that could easily be missed by the traditional treatment approach.

But the results of the first big test for this potentially game changing technology are about to be released in the next couple of weeks.

THE HeraMED SHARE PRICE AT THE TIME OF PUBLISHING THIS ARTICLE WAS $0.155.

The TradingView chart below is live but delayed 20 minutes if the market is open.